CHICAGO, Aug. 10, 2012 /PRNewswire/ --Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Dr. Reddy's Laboratories (NYSE:RDY), Merck & Co (NYSE:MRK), Mylan Inc. (Nasdaq:MYL), Pfizer, Inc. (NYSE:PFE) and Roche (OTC:RHHBY).
(Logo: http://photos.prnewswire.com/prnh/20101027/ZIRLOGO)
Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513
Here are highlights from Thursday's Analyst Blog:
Dr. Reddy's Expands Portfolio
Dr. Reddy's Laboratories (NYSE:RDY) recently announced the launch of its generic version of Merck & Co's (NYSE:MRK) blockbuster asthma and allergy drug Singulair (montelukast) following the receipt of US Food & Drug Administration (FDA) approval for its Abbreviated New Drug Application (ANDA).
Dr. Reddy's launched its generic version of Singulair tablets (10 mg) and chewable tablets (4 mg & 5 mg) in the US on August 6, 2012. Singulair is marketed for the chronic treatment of asthma symptoms and relieving symptoms of allergic rhinitis in both adults and children.
According to IMS Health, US branded sales of Singulair tablets and chewable tablets were approximately $3.6 billion and $1.14 billion, respectively, for the twelve months ended March 31, 2012.
Earlier this month, Singulair lost patent exclusivity in the US. Notably, Mylan Inc. (Nasdaq:MYL) also launched its generic version of Singulair tablets (10 mg) and chewable tablets (4mg &5 mg) following FDA approval.
Dr. Reddy's had quite a few generic launches this year. In July 2012, it launched its generic version of Pfizer, Inc.'s (NYSE:PFE) blockbuster cholesterol drug, Lipitor. The FDA had approved the company's ANDA for its generic version of Lipitor (10 mg, 20 mg, 40 mg and 80 mg formulations). Lipitor lost patent exclusivity in the US on November 30, 2011.
Dr. Reddy's also launched a generic version of Roche's (OTC:RHHBY) Boniva tablets for the treatment of osteoporosis in women after menopause.
Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: http://at.zacks.com/?id=5515.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: http://at.zacks.com/?id=5517
About Zacks
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leon Zacks. As a PhD from MIT Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=5518.
Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com
SOURCE Zacks Investment Research, Inc.
